← Leaderboards
Resham Bhattacharya
University Of Oklahoma Hlth Sciences Ctr
$4,398,302
Attributed
$7,072,758
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,072,758 · 7
By mechanism
R01$6,922,541 · 5
P30$150,217 · 2
Top collaborators
- Priyabrata Mukherjee15 shared
Most similar at University Of Oklahoma Hlth Sciences Ctr
Same institution · by research overlap
- Priyabrata Mukherjee$10,375,168
- Stefano Tarantini$1,090,155
- Shailendra Kumar Dhar Dwivedi$169,469
Others in their field
Top investigators on “Small Interfering Rna”
- Randall J Bateman · Washington University$62,939,456
- Thomas William Geisbert · Boston University Medical Campus$30,074,519
- Judy Lieberman · Boston Children'S Hospital$24,680,725
- Michael Welch · Washington University$18,835,712
- Anastasia Khvorova · Rxi Pharmaceuticals Corporation$17,475,922
- Michael P Czech · Univ Of Massachusetts Med Sch Worcester$15,688,365
Research focus
Small Interfering RnaIn VitroIn VivoReportingMalignant Neoplasm Of OvaryCancer CellTumorPathway InteractionsTumor GrowthDrug ResistanceOverexpressionMitochondriaResistanceProteinsAnimal ModelMolecularCellsCisplatinTissuesTreatment EfficacyApoptosisSignal TransductionMediatingMalignant Neoplasms
Grant awards (23)
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system$367,289
R01 · FY2025 · CA
Exploiting gold nanoparticle as a probe to identify therapeutic targets$354,959
R01 · FY2025 · CA
Protein-nanoparticle interaction to study multicellular crosstalk within ovarian tumor microenviroment$326,103
R01 · FY2025 · CA
Cancer Biology Program$48,755
P30 · FY2025 · CA · contact PI
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system$346,423
R01 · FY2024 · CA
Exploiting gold nanoparticle as a probe to identify therapeutic targets$78,953
R01 · FY2024 · CA
Cancer Biology Program$50,732
P30 · FY2024 · CA · contact PI
Exploiting gold nanoparticle as a probe to identify therapeutic targets$379,984
R01 · FY2023 · CA
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system$376,116
R01 · FY2023 · CA
Cancer Biology Program$50,730
P30 · FY2023 · CA · contact PI
Exploiting gold nanoparticle as a probe to identify therapeutic targets$398,989
R01 · FY2022 · CA
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system$310,077
R01 · FY2022 · CA
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system$316,405
R01 · FY2021 · CA
Cystathionine beta synthase (CBS) and angiogenesis$421,311
R01 · FY2017 · HL
Cystathionine beta synthase (CBS) and angiogenesis$422,373
R01 · FY2016 · HL
Bmi-1, a potential therapeutic target in ovarian cancer$311,480
R01 · FY2016 · CA · contact PI
Cystathionine beta synthase (CBS) and angiogenesis$417,052
R01 · FY2015 · HL
Bmi-1, a potential therapeutic target in ovarian cancer$311,480
R01 · FY2015 · CA · contact PI
Cystathionine beta synthase (CBS) and angiogenesis$415,917
R01 · FY2014 · HL
Bmi-1, a potential therapeutic target in ovarian cancer$302,136
R01 · FY2014 · CA · contact PI
Cystathionine beta synthase (CBS) and angiogenesis$416,962
R01 · FY2013 · HL
Bmi-1, a potential therapeutic target in ovarian cancer$304,071
R01 · FY2013 · CA · contact PI
Bmi-1, a potential therapeutic target in ovarian cancer$344,461
R01 · FY2012 · CA · contact PI